ArticleDiabetes2018
Improved Murine MHC-Deficient HLA Transgenic NOD Mouse Models for Type 1 Diabetes Therapy Development.
Open access · bronzeAbstract read
In one paragraph
Article in Diabetes, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 23 citations in OpenAlex.
- Murine and Humanized Mouse Models in Autoimmune Disease Research and Therapeutics Development.Biology · 2026Review
- Is the NOD mouse a good model for type 1 diabetes?Diabetologia · 2026Review
- Anti-CD3 microporous annealed particle hydrogel protects stem cell derived beta cells from autoreactive T cells.bioRxiv : the preprint server for biology · 2025Article
- Humanized Mouse Models for Type 1 Diabetes.Current protocols · 2025Review
- Preclinical mouse models of immune checkpoint inhibitor-associated myocarditis.Nature cardiovascular research · 2025Review
- Advancing Animal Models of Human Type 1 Diabetes.Cold Spring Harbor perspectives in medicine · 2024Review
- Murine MHC-Deficient Nonobese Diabetic Mice Carrying Human HLA-DQ8 Develop Severe Myocarditis and Myositis in Response to Anti-PD-1 Immune Checkpoint Inhibitor Cancer Therapy.Journal of immunology (Baltimore, Md. : 1950) · 2024Article
- Autoimmune CD8+ T cells in type 1 diabetes: from single-cell RNA sequencing to T-cell receptor redirection.Frontiers in endocrinology · 2024Review
- Application and perspective of CRISPR/Cas9 genome editing technology in human diseases modeling and gene therapy.Frontiers in genetics · 2024Review
- Applications of Genome-Editing Technologies for Type 1 Diabetes.International journal of molecular sciences · 2023Review
- HLA-DQ8 Supports Development of Insulitis Mediated by Insulin-Reactive Human TCR-Transgenic T Cells in Nonobese Diabetic Mice.Journal of immunology (Baltimore, Md. : 1950) · 2023Article
- Preclinical Models to Evaluate the Human Response to Autoantigen and Antigen-Specific Immunotherapy in Human Type 1 Diabetes.Frontiers in endocrinology · 2022Review
- Human stem cell derived beta-like cells engineered to present PD-L1 improve transplant survival in NOD mice carrying human HLA class I.Frontiers in endocrinology · 2022Article
- A Humanized Mouse Strain That Develops Spontaneously Immune-Mediated Diabetes.Frontiers in immunology · 2021Article
- Model validity for preclinical studies in precision medicine: precisely how precise do we need to be?Mammalian genome : official journal of the International Mammalian Genome Society · 2019Article
- The Evolving Landscape of Autoantigen Discovery and Characterization in Type 1 Diabetes.Diabetes · 2019Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 1 country.
Jeremy J RacineThe Jackson Laboratory, Bar Harbor, ME.
Isabel StewartThe Jackson Laboratory, Bar Harbor, ME.
Jeremy RatiuThe Jackson Laboratory, Bar Harbor, ME.
Greg ChristiansonThe Jackson Laboratory, Bar Harbor, ME.
Emily LowellThe Jackson Laboratory, Bar Harbor, ME.
Kelsay HelmThe Jackson Laboratory, Bar Harbor, ME.
Jennifer AlloccoThe Jackson Laboratory, Bar Harbor, ME.
Richard S MaserThe Jackson Laboratory, Bar Harbor, ME.
Yi-Guang ChenMedical College of Wisconsin, Milwaukee, WI.
Cathleen M LutzThe Jackson Laboratory, Bar Harbor, ME.
Derry RoopenianThe Jackson Laboratory, Bar Harbor, ME.
Jennifer SchlossAlbert Einstein College of Medicine, Bronx, NY.
Teresa P DiLorenzoAlbert Einstein College of Medicine, Bronx, NY.
David V SerrezeThe Jackson Laboratory, Bar Harbor, ME dave.serreze@jax.org.ORCID 0000-0001-7614-5925
Jackson Laboratory · USAlbert Einstein College of Medicine · USMedical College of Wisconsin · US
Funding
WORD PROCESSORP30CA013330 · NCI · YESHIVA UNIVERSITY · PI STEVEN C. ALMO · 1985 to 2026
$111.2MShared Resource ManagementP30CA034196 · NCI · JACKSON LABORATORY · PI William Carl Skarnes · 1985 to 2026
$61.9MMEDICAL SCIENTIST TRAINING PROGRAMT32GM007288 · NIGMS · YESHIVA UNIVERSITY · PI AKABAS, MYLES H. · 1985 to 2022
$35.6MStable Isotope and Metabolomics CoreP60DK020541 · NIDDK · YESHIVA UNIVERSITY · PI PESSIN, JEFFREY E. · 1986 to 2014
$29.8MThe Mutant Mouse Resource and Research Center at The Jackson LaboratoryU42OD010921 · OD · JACKSON LABORATORY · PI LAURA G REINHOLDT · 2012 to 2026
$21.4MThe Jackson Laboratory Center for Precision Genetics: From New Models to Novel TherapeuticsU54OD020351 · OD · JACKSON LABORATORY · PI LUTZ, CATHLEEN M · 2015 to 2019
$10.2MDiabetogenic Role of MHC Class I Alleles in NOD MiceR01DK046266 · NIDDK · JACKSON LABORATORY · PI SERREZE, DAVID V · 2000 to 2018
$7.2MB-lymphocyte Targeting Therapies for Autoimmune DiabetesR01DK095735 · NIDDK · JACKSON LABORATORY · PI SERREZE, DAVID V · 2013 to 2025
$6.2MMechanistic and Therapeutic Role of the CD137-CD137L Axis in Type 1 DiabetesR01DK107541 · NIDDK · MEDICAL COLLEGE OF WISCONSIN · PI CHEN, YI-GUANG, RIDGWAY, WILLIAM M · 2016 to 2025
$5.6MAntigens Recognized by CD8+ T Cells in Type 1 DiabetesR01DK064315 · NIDDK · YESHIVA UNIVERSITY · PI DILORENZO, TERESA P · 2003 to 2015
$3.8MT Cell Tolerance by DEC-205-mediated Islet Antigen Delivery to Dendritic CellsR01DK094327 · NIDDK · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI DILORENZO, TERESA P · 2011 to 2015
$1.8MSummer Research Experience in Cancer Biology and Genomics for UndergraduatesR25CA174584 · NCI · JACKSON LABORATORY · PI SHULTZ, LEONARD · 2013 to 2017
$243kNCI NIH HHS P30 CA013330NCI NIH HHS P30 CA034196NCI NIH HHS R25 CA174584NIAID NIH HHS R03 AI119225NIDDK NIH HHS F30 DK103368NIDDK NIH HHS F32 DK111078NIDDK NIH HHS P60 DK020541NIDDK NIH HHS R01 DK046266NIDDK NIH HHS R01 DK064315NIDDK NIH HHS R01 DK094327NIDDK NIH HHS R01 DK095735NIDDK NIH HHS R01 DK107541NIDDK NIH HHS R29 DK046266NIGMS NIH HHS T32 GM007288NIH HHS U42 OD010921NIH HHS U54 OD020351
Abstract
Improved mouse models for type 1 diabetes (T1D) therapy development are needed. T1D susceptibility is restored to normally resistant NOD.β2m
Indexed as
Disease Models, AnimalMiceAnimalsbeta 2-MicroglobulinCRISPR-Cas SystemsDiabetes Mellitus, Type 1Histocompatibility Antigens Class IHLA-A2 AntigenHLA-B AntigensHumansMice, Inbred NODMice, KnockoutMice, Transgenicbeta 2-MicroglobulinHistocompatibility Antigens Class IHLA-A*02:01 antigenHLA-A2 AntigenHLA-B Antigens
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.